[go: up one dir, main page]

MX2012001420A - Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus. - Google Patents

Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.

Info

Publication number
MX2012001420A
MX2012001420A MX2012001420A MX2012001420A MX2012001420A MX 2012001420 A MX2012001420 A MX 2012001420A MX 2012001420 A MX2012001420 A MX 2012001420A MX 2012001420 A MX2012001420 A MX 2012001420A MX 2012001420 A MX2012001420 A MX 2012001420A
Authority
MX
Mexico
Prior art keywords
formula
pyrrolo
kinase inhibitors
janus kinase
pyridazine derivatives
Prior art date
Application number
MX2012001420A
Other languages
English (en)
Inventor
V Satish Kumar
Pravin L Kotian
Minwan Wu
Yarlagadda S Babu
Tsu-Hsing Lin
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MX2012001420A publication Critical patent/MX2012001420A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona compuestos de la fórmula I (ver fórmula (I)) o una sal de los mismos como se describe en la presente. La invención también proporciona composiciones farmacéuticas que comprenden el compuesto de la fórmula I, procedimientos para preparar los compuestos de la fórmula I, intermediarios útiles para preparar compuestos de la fórmula I y métodos terapéuticos para suprimir una respuesta inmune o tratar cáncer o una malignidad hematológica usando los compuestos de la fórmula I.
MX2012001420A 2009-07-31 2010-07-30 Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus. MX2012001420A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23049009P 2009-07-31 2009-07-31
PCT/US2010/043987 WO2011014817A1 (en) 2009-07-31 2010-07-30 Pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2012001420A true MX2012001420A (es) 2012-03-26

Family

ID=42670611

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001420A MX2012001420A (es) 2009-07-31 2010-07-30 Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.

Country Status (14)

Country Link
US (1) US20120149691A1 (es)
EP (1) EP2459562A1 (es)
JP (1) JP2013501003A (es)
KR (1) KR20120085738A (es)
CN (1) CN102596959A (es)
AR (1) AR077346A1 (es)
AU (1) AU2010278730A1 (es)
BR (1) BR112012002110A2 (es)
CA (1) CA2769209A1 (es)
IL (1) IL217798A0 (es)
MX (1) MX2012001420A (es)
RU (1) RU2012107101A (es)
TW (1) TW201107330A (es)
WO (1) WO2011014817A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN106074548A (zh) 2010-09-23 2016-11-09 艾伯维巴哈马有限公司 氮杂金刚烷衍生物的一水合物
EP2685981B1 (en) * 2011-03-17 2016-08-24 Bristol-Myers Squibb Company Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
TW201249846A (en) * 2011-03-17 2012-12-16 Bristol Myers Squibb Co Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
US9221826B2 (en) 2011-03-17 2015-12-29 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2012172043A1 (en) 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
US9428511B2 (en) * 2012-09-06 2016-08-30 Bristol-Myers Squibb Company Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
EP2892880B1 (en) 2012-09-07 2017-11-22 Novartis AG Indole carboxamide derivatives and uses thereof
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
PL233595B1 (pl) 2017-05-12 2019-11-29 Celon Pharma Spolka Akcyjna Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK
CN109232575B (zh) * 2017-07-10 2022-01-25 中国科学院上海药物研究所 吡咯[1,2-b]哒嗪类化合物或其可药用盐及它们的用途
TWI721483B (zh) * 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CA3125039A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
EP3999512B1 (en) 2019-07-18 2023-08-23 Bristol-Myers Squibb Company Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as irak4 inhibitors
JP7570399B2 (ja) 2019-07-18 2024-10-21 ブリストル－マイヤーズ スクイブ カンパニー Ｉｒａｋ４阻害剤として有用な三環式ヘテロアリール化合物
EP4004000B1 (en) 2019-07-23 2025-07-09 Bristol-Myers Squibb Company Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors
EP4010317B1 (en) 2019-08-06 2024-06-19 Bristol-Myers Squibb Company Bicyclic heterocyclic compounds useful as irak4 inhibitors
CN114206874B (zh) * 2019-08-13 2024-08-02 百时美施贵宝公司 可用作irak4抑制剂的双环杂芳基化合物
US12391702B2 (en) 2020-02-03 2025-08-19 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2022109492A1 (en) * 2020-11-23 2022-05-27 Gossamer Bioservices, Inc. Pyrrolopyridazine compounds as kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US6900208B2 (en) * 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CN101312977B (zh) * 2005-09-22 2012-06-13 布里斯托尔-迈尔斯.斯奎布公司 用作激酶调节剂的稠合杂环化合物
US7531539B2 (en) * 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
BRPI0718266A2 (pt) * 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
US8389527B2 (en) * 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
CA2732628A1 (en) 2008-08-01 2010-02-04 Biocryst Pharmaceuticals, Inc. Therapeutic agents

Also Published As

Publication number Publication date
CN102596959A (zh) 2012-07-18
BR112012002110A2 (pt) 2018-04-10
CA2769209A1 (en) 2011-02-03
AR077346A1 (es) 2011-08-17
IL217798A0 (en) 2012-03-29
WO2011014817A1 (en) 2011-02-03
AU2010278730A1 (en) 2012-03-01
EP2459562A1 (en) 2012-06-06
RU2012107101A (ru) 2013-09-10
JP2013501003A (ja) 2013-01-10
KR20120085738A (ko) 2012-08-01
TW201107330A (en) 2011-03-01
US20120149691A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
MX2012001420A (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.
WO2011031554A3 (en) Heterocyclic compounds as janus kinase inhibitors
WO2011079230A3 (en) Heterocyclic compounds as janus kinase inhibitors
HK1202541A1 (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
TW200800990A (en) Azaindole inhibitors of aurora kinases
MX2011012037A (es) Compuestos de heteroarilo como inhibidores de pikk.
MX370390B (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
UA99597C2 (ru) Пиримидилциклопентаны как ингибиторы акт протеинкиназ
WO2009155121A3 (en) Inhibitors of pi3 kinase
MX2020003458A (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
MX2009004699A (es) Compuestos de piridinona.
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
PE20090506A1 (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
IN2014KN02886A (es)
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
BR112012029994A2 (pt) composto heterocíclicos como inibidores de janus quinase
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
UA100545C2 (ru) Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт

Legal Events

Date Code Title Description
FA Abandonment or withdrawal